Insider Transactions last 24 months for Enliven Therapeutics, Inc.  -  NSDQ: ELVN

 
Transactions
All Buy Sell Option Exercise
Filer's Name
Relationship/
Title
Trans.
Date
Trans. Type
Ownership Type
Security Type
Shares
Price
Trans.
Value
Total Shares Owned
Collins Helen LouiseCHIEF MEDICAL OFFICER03/25/2026DSDirectCOM40,000$35.10$1,404,024.0025,000
Collins Helen LouiseCHIEF MEDICAL OFFICER03/25/2026AMDirectCOM40,000$2.48$99,200.0065,000
Collins Helen LouiseCHIEF MEDICAL OFFICER03/17/2026DSDirectCOM5,000$27.76$138,800.0025,000
Collins Helen LouiseCHIEF MEDICAL OFFICER03/17/2026AMDirectCOM5,000$2.48$12,400.0030,000
Collins Helen LouiseCHIEF MEDICAL OFFICER03/10/2026DSDirectCOM10,129$30.19$305,826.9225,000
Collins Helen LouiseCHIEF MEDICAL OFFICER03/10/2026AMDirectCOM10,129$2.48$25,119.9235,129
Collins Helen LouiseCHIEF MEDICAL OFFICER03/09/2026DSDirectCOM29,871$30.02$896,811.0625,000
Collins Helen LouiseCHIEF MEDICAL OFFICER03/09/2026AMDirectCOM29,871$2.48$74,080.0854,871
Hohl BenjaminCHIEF FINANCIAL OFFICER03/06/2026DSDirectCOM10,000$29.58$295,839.0051,000
Heyman Richard A.Director02/17/2026DSIndirectCOM1,230$26.18$32,196.3622,647
Collins Helen LouiseCHIEF MEDICAL OFFICER02/17/2026DSDirectCOM45,000$26.17$1,177,861.5025,000
Collins Helen LouiseCHIEF MEDICAL OFFICER02/17/2026AMDirectCOM45,000$2.48$111,600.0070,000
Collins Helen LouiseCHIEF MEDICAL OFFICER02/12/2026AADirectCOM25,000$0.00$0.0025,000
Hohl BenjaminCHIEF FINANCIAL OFFICER02/12/2026AADirectCOM25,000$0.00$0.0061,000
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER02/12/2026AADirectCOM18,750$0.00$0.0018,750
Patel AnishCHIEF OPERATING OFFICER02/12/2026AADirectCOM20,000$0.00$0.0020,000
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER02/06/2026DSIndirectCOM5,000$29.04$145,219.00740,188
Heyman Richard A.Director01/20/2026DSIndirectCOM718$26.96$19,354.4123,877
Heyman Richard A.Director01/20/2026DSIndirectCOM512$26.46$13,547.1124,595
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER01/20/2026DSIndirectCOM14,509$26.90$390,284.85745,188
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER01/20/2026DSIndirectCOM5,491$26.37$144,814.14759,697
Heyman Richard A.Director01/09/2026DSIndirectCOM4,285$25.00$107,125.4325,107
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER01/09/2026DSIndirectCOM50,000$29.13$1,456,715.00765,188
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER01/09/2026DSIndirectCOM41,198$24.90$1,025,863.16815,188
Patel AnishCHIEF OPERATING OFFICER01/09/2026DSIndirectCOM243$28.50$6,925.50215,011
1   2  3  4  5  6  7  8  9  10  Next Last  You are at page 1 of 11 pages
Transaction Type Key
First letter: A = Acquired, D = Disposed
Second letter:
A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust
Export Table Data to Excel Send to Excel